gutflix
GI learning, personalised

Summary

IMPLICATIONS OF TIOGUANINE DOSING IN IBD PATIENTS WITH A TPMT DEFICIENCY

Dennis R. Wong

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A retrospective cohort study found that tioguanine can be safely used in IBD patients with aberrant TPMT metabolism when dose-adjusted and closely monitored.

KEY POINTS

- Among 485 patients genotyped, 10.3 percent were intermediate TPMT metabolisers and 0.8 percent were poor metabolisers.
- One poor TPMT metaboliser experienced delayed pancytopenia on tioguanine 10 mg daily, demonstrating risk of late-occurring myelotoxicity at standard doses.
- Reduced dosing of 5 mg daily for intermediate metabolisers and 10 mg two-weekly for poor metabolisers resulted in safe, long-term treatment.
- With strongly reduced dose regimens and strict therapeutic drug and safety monitoring, tioguanine remained a safe and effective option in IBD patients with dysfunctional TPMT.
- This material is relevant for gastroenterologists managing IBD patients with known or suspected TPMT enzyme deficiency who are considering thiopurine therapy.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e5afc104-743b-11ee-ad45-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.